Moderna Inc.’s Covid vaccine generated more than double the
antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research that compared immune responses
evoked by the two inoculations.
The study
is one of the first to compare levels of antibodies produced by the two
vaccines, which are thought to be one of the important components of the immune
response. It didn’t examine whether the antibody differences led to a
difference in efficacy over time between the two shots, which both were more
than 90% effective in final-stage clinical trials.
The research looked
at antibody levels against the coronavirus spike protein in about 1,600 workers
at a major Belgium hospital system whose blood samples were analyzed 6 to 10
weeks after vaccination. The participants hadn’t been infected with the
coronavirus before getting vaccinated. Levels among those who got two doses of
the Moderna vaccine averaged 2,881 units per milliliter, compared with 1,108
units per milliliter among those who received two Pfizer doses.
The results, published
Monday in a letter to the Journal of the American Medical Association,
suggested the differences might be explained by the higher amount of active
ingredient in the Moderna vaccine -- 100 micrograms,
versus 30 micrograms in
Pfizer-BioNTech -- or the slightly longer interval between doses of the Moderna
vaccine -- four weeks, versus three weeks for Pfizer-BioNTech.
The antibody response to vaccines among >1600 health
care workers:
--@Moderna_tx significantly exceeded Pfizer
(median titer 3836 vs 1444 U/mL)
--Prior covid higher than no prior infection
(median titer 9461 vs 1613 U/ML)https://t.co/QurRfa68Xi… @JAMA_current pic.twitter.com/x0DhN95thI
— Eric Topol (@EricTopol)August 30, 2021
Outside
researchers said it was premature to conclude that the difference in antibody
levels was medically important.
“I would urge caution in making the conclusion
that because Moderna demonstrated a slightly higher peak on average that its
efficacy will be slower to wane,” said David Benkeser,
a biostatistician at Emory University, in an email. “Such a conclusion requires
a host of assumptions that have not yet been evaluated.”
Both
vaccines produce high levels of antibodies, he noted, and other studies have
shown even relatively low levels of antibodies are protective.
Still, it’s possible that
higher initial antibody levels might correlate with longer duration of
protection against mild breakthrough infections, said Deborah Steensels, a
microbiologist at Ziekenhuis Oost-Limburg, a large hospital in Belgium, who was
lead author on the study. Also, if higher antibody levels are confirmed
to be important, then the Moderna vaccine might be better for immunocompromised
people who don’t respond well to vaccines, she said.
Pfizer
said in a statement that its vaccine “continues to be highly efficacious” in
preventing Covid-19, including against severe cases and hospitalization. A
continuing analysis of its final-stage study has shown a decline of efficacy
against symptomatic infection over time, the drugmaker said, but initial trial
data also show that a third dose of the existing vaccine at least six months
after the first two significantly raises neutralizing antibody levels.
Moderna’s vaccine was
associated with a two-fold risk reduction against breakthrough SARS-CoV-2
infections compared to Pfizer’s in a review of people in the Mayo Clinic Health
System in the U.S. from January to July. The results were reported in a
separate study released
ahead of publication and peer review on Aug. 9.